Navigation Links
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Date:12/13/2007

The U.S. Food and Drug Administration (FDA) has accepted for filing the

Supplemental New Drug Application (sNDA) for the use of Neupro(R) (Rotigotine Transdermal System) as adjunctive therapy with levodopa in

adult patients with advanced-stage Parkinson's disease

ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson's disease has been accepted for filing by the U.S. Food and Drug Administration (FDA).

The FDA has already approved Neupro(R) for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease and the drug has been commercially available in the United States since July 2007.

"We are excited that patients with all stages of Parkinson's disease may soon benefit from Neupro(R)'s 24-hour continuous drug delivery," said Troy Cox, President CNS Operations, UCB.

The sNDA is based on efficacy and safety data in more than 670 patients with advanced-stage Parkinson's disease who were treated with rotigotine in three double-blind, placebo-controlled clinical trials. These studies demonstrated that rotigotine, as adjunctive therapy to levodopa in patients with advanced-stage Parkinson's disease, showed clinically relevant reductions in "off" time (periods where the effectiveness of medications wear off and Parkinson's symptoms return) and favorable increases in "on" time without troublesome dyskinesia (fragmented or jerky movements). The most frequently-reported adverse events in rotigotine clinical trials included application site reactions, nausea, vomiting, dizziness, somnolence and dyskinesia.

"As these clinical studies have shown, continuous delivery of rotigotine in a transdermal form can improve control of 'off' time in advanced-stage Parkinson's patients throughout the day and night. Once-daily dosing may improve compl
'/>"/>

SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
2. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
3. First Nationwide Class Action Filed Against ConAgra on Behalf of Consumers Who Purchased or Ingested Salmonella Contaminated Pot Pies
4. Federal Charges Filed Against Community Medical Centers Management
5. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
6. Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Another Medtronic Sprint Fidelis Lead Lawsuit is Filed in Federal District Court
8. Class Action Lawsuit Filed Against 15 California Nursing Homes
9. New treatment effective in counteracting cocaine-induced symptoms
10. New treatment boosts muscle function in myasthenia gravis
11. Broad-based group of physicians calls for improvement in stroke treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 The Clinical Data ... that the International Organization for Standardization (ISO) now ... (BRIDG) Model version 3.2 as a published, Final ... with healthcare. This standard, which had previously passed ... was unanimously approved on 24 April for publication ...
(Date:5/28/2015)... 28, 2015 Park Cities Pet Sitter is ... Training class starting Saturday, June 6th at 10:30am. ... 5831 McCommas Blvd in Dallas, with a maximum of six ... for five weeks, with no class being held over the ... $135. , In this Intermediate-to-Advanced level class, dogs will solidify ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... opening a new location for his Shore Vascular & Vein ... treatment of the circulatory system. It is his mission ... compassion, consideration and respect. , Dr. Jeffrey Gosin ... a graduate of the University of Pennsylvania and Jefferson Medical ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... plays a major role in kidney failure, and blocking the ... disease in diabetes, according to researchers. "We believe these ... can slow down the progression of, or even prevent the ... professor of nephrology, Penn State College of Medicine. In the ...
... News) -- Low vitamin D levels are common among spine ... says. Vitamin D helps with calcium absorption. Spine surgery ... producing new bone, explained researchers at Washington University School of ... spinal fusion surgery and found that more than half of ...
... , FRIDAY, Nov. 4 (HealthDay News) -- "Leatherhead" football ... modern helmets, a new study reports, but no one is ... researchers said their findings point to the need for improvements ... research team conducted lab tests to compare head injury risks ...
... crystallography, researchers Xiaohu Mei, PhD, and David Atkinson, PhD, from ... time obtained an "image" of the structure and the precise ... apolipoprotein A-I (apoA-I) molecule. The findings, which appear in the ... may lead to the development of new drugs to treat ...
... a new study being published early online in Annals ... College of Physicians, birth cohort screening for hepatitis C is ... strategy could identify over 800,000 currently unidentified cases, which could ... percent of the nation,s population is infected with hepatitis C ...
... A gene variation associated with an increased risk of autism ... three to four times more likely than girls to be ... genomic data from more than 3,000 children with autism and ... The results showed a link between a variation in the ...
Cached Medicine News:Health News:Research aims to prevent diabetic kidney failure 2Health News:Vitamin D Lacking in Many Spine Surgery Patients 2Health News:Newer Not Necessarily Better for Football Helmet Design 2Health News:Researchers identify structure of apolipoprotein 2Health News:Birth cohort screening for hepatitis C is cost effective, could save thousands of lives each year 2Health News:Possible Genetic Link to Autism Identified 2
(Date:5/28/2015)... 28, 2015 National Community Pharmacists Association (NCPA) ... the following statement in response to a new ... documenting that a number of generic drug costs increased ... with concerns previously expressed by NCPA and underscores the ... to essential medications. Moreover, a 2015 survey of 700 ...
(Date:5/28/2015)... , May 27, 2015 The amount ... billion in 2014 and with growth of 8% will ... categories out of pocket: directly on expenditures, co-pays as ... purchases, and on premiums.  The publisher made its finding ... in the United States . ...
(Date:5/28/2015)...  The U.S. Department of Justice (DOJ) has entered ... Medical Inc. to resolve a lawsuit that began more ... whistleblower lawsuit by two former employees of Orbit.  The ... of one of Orbit,s top executives, Jake Kilgore ... payment from Medicare for electric wheelchairs.  The lawsuit was ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
... and FOSTER CITY, Calif., Dec. 11 /PRNewswire-FirstCall/,-- ... and Gilead Sciences, Inc.,(Nasdaq: GILD ) ... 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ... suppressed adults with,HIV-1 infection, subject to the ...
... Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) announced today ... CPOP-R to CHOP-R in the,first-line treatment of patients with ...
Cached Medicine Technology:Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
An economical solution to the need to provide wrap-around protection. The one-sided velcro closure allows greater flexibility in sizing. Front protection is 0.5mm Pb and the back is 0.25mm Pb equival...
This wrap around apron features a uniquely designed orthopedic wide belt that is integrated directly on the apron....
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Medicine Products: